Lavina Pharma

Pharmaceutical manufacturing and exporting of preparations in India.

About Lavina Pharma

Lavina Pharma is a Healthcare company. Pharmaceutical manufacturing and exporting of preparations in India. Its Indian entity Lavina Pharmaceuticals Private Limited reported revenue of β‚Ή27.56 Cr. Lavina Pharma offers products and services including Tablets and Injections. Its focus areas include Pharmaceuticals, Drug Manufacturing, Finished Products and Nutraceuticals.

Company details

Lavina Pharma is recognized as an integrated pharmaceutical export house that was established in 2004, focusing on the manufacturing and global distribution of a broad range of pharmaceutical preparations. Products are supplied to diverse markets, covering therapeutic areas such as analgesics and immunology, with an emphasis on quality manufacturing and regulatory compliance. Affordable medicines and formulations are offered, including finished products and raw materials, to support healthcare needs across continents, while partnerships are formed to expand global presence and ensure access to preventive healthcare solutions.

Key Metrics
  • Indian entity revenue
    ₹27.56 Cr

    FY 2025 · -12% YoY

  • Indian entity net profit
    ₹67.2 Lakh

    FY 2025 · 2% margin

  • Indian entity EBITDA
    ₹1.79 Cr

    FY 2025 · 7% margin

Products & Services of Lavina Pharma

Lavina Pharma offers a comprehensive portfolio of products and services, including Tablets and Injections.

Tablets
Pharmaceutical Products

Tablets are manufactured for immediate release and sustained formulations to treat various diseases.

Injections
Pharmaceutical Products

Injections are provided in small volume and dry powder forms for medical treatments across therapeutic areas.

Board of directors of Lavina Pharmaceuticals Private Limited (Lavina Pharma)

Lavina Pharmaceuticals Private Limited is the primary company behind Lavina Pharma. The board of Lavina Pharmaceuticals Private Limited currently have 2 directors; the longest-serving is Jagdish Singh Deb Singh Shawant, appointed in 2004.

DirectorDesignationAppointedTenureEntity
Jagdish Singh Deb Singh Shawant
DIN 00455793
Director03 Dec 200421 yrs 11 moLavina Pharmaceuticals Private Limited
Mala Jagdish Shawant
DIN 00455914
Director03 Dec 200421 yrs 11 moLavina Pharmaceuticals Private Limited

Financials of Lavina Pharma

Figures of Lavina Pharmaceuticals Private Limited, the primary company behind Lavina Pharma, for FY 2025. Revenue was ₹27.56 Cr (-12% year on year). Net profit was ₹67.2 Lakh (2% margin). EBITDA was ₹1.79 Cr (7% margin). Revenue has grown at a compounded annual rate of -5% over three years and +4% over five years.

  • ₹27.56 CrRevenue · FY 2025 · -12% YoY
  • ₹67.2 LakhNet profit · 2% margin
  • ₹1.79 CrEBITDA · 7% margin
  • ₹25 LakhPaid-up capital
  • -5%Revenue CAGR, 3 years
  • +4%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Lavina Pharmaceuticals Private Limited are on its company page.

Premium access

Detailed financial statements for Lavina Pharma

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Lavina Pharma

The primary company behind Lavina Pharma, Lavina Pharmaceuticals Private Limited, reported revenue of β‚Ή27.56 Cr for FY 2025, down 12% year on year.

Lavina Pharma is recognized as an integrated pharmaceutical export house that was established in 2004, focusing on the manufacturing and global distribution of a broad range of pharmaceutical preparations. Products are supplied to diverse markets, covering therapeutic areas such as analgesics and immunology, with an emphasis on quality manufacturing and regulatory compliance. Affordable medicines and formulations are offered, including finished products and raw materials, to support healthcare needs across continents, while partnerships are formed to expand global presence and ensure access to preventive healthcare solutions.

Lavina Pharma offers Tablets and Injections.

Lavina Pharma operates through Lavina Pharmaceuticals Private Limited.

The legal entities of Lavina Pharma currently have 2 directors, including Jagdish Singh Deb Singh Shawant, Mala Jagdish Shawant.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available